CNMD — CONMED Corporation stock price, charts and financials

QT73CONMED Corporation

CONMED Corporation (NYSE: CNMD) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
45.42
-0.71-1.54%
CNMDQT73CONMED Corporation·NYSE
45.42-1.54%
News
Down 1.5% — 1 Unpopular Stock That Should Get More Attention and 2 We Turn Down (Yahoo).
Medium confidence
TA
Loading chart...
Screen all →
Snapshot
Index-P/E24.52EPS (ttm)1.85Insider Own2.98%Shs Outstand29.95MPerf Week-1.90%
Market Cap1.36BForward P/E9.50EPS next Y4.78Insider Trans0.00%Shs Float29.82MPerf Month-11.38%
Enterprise Value2.16BPEG-EPS next Q1.00Inst Own-Short Float7.59%Perf Quarter39.41%
Income56.32MP/S0.99EPS this Y145.17%Inst Trans-Short Ratio3.76Perf Half Y23.42%
Sales1.37BP/B1.31EPS next Y5.42%ROA2.46%Short Interest2.26MPerf YTD11.87%
Book/sh-P/C9.07EPS next 5Y10.44%ROE5.51%52W High53.66 -15.36%Perf Year-10.02%
Cash/sh-P/FCF10.12EPS past 3/5Y- 36.38%ROIC4.97%52W Low31.44 44.47%Perf 3Y-57.74%
Dividend Est.0.80 (1.76%)EV/EBITDA11.99Sales past 3/5Y9.55% 9.77%Gross Margin54.80%Volatility2.80% 2.98%Perf 5Y-63.06%
Dividend TTM0.20 (0.44%)EV/Sales1.57EPS Y/Y TTM-56.57%Oper. Margin10.79%ATR (14)1.59Perf 10Y7.91%
Dividend Ex-DateSep 15, 2025Quick Ratio0.69Sales Y/Y TTM4.97%Profit Margin4.12%RSI (14)37.17Recom2.71
Dividend Gr. 3/5Y-9.14% -5.59%Current Ratio1.48EPS Q/Q20.00%SMA20-6.31%Beta0.95Target Price37.50
Payout21.91%Debt/Eq0.80Sales Q/Q0.00%SMA50-3.73%Rel Volume1.44Prev Close46.13
Employees3,900LT Debt/Eq0.81EarningsNov 04SMA20011.67%Avg Volume540.93KPrice45.42
IPO DateJul 23, 1987Option/ShortYes / YesEPS/Sales Surpr.24.32% 1.75%Net Debt/EBITDA4.43Volume780,477Change-1.54%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-13-26ReiteratedWells FargoEqual Weight$39
Jul-08-26InitiatedBMO CapitalMarket Perform$36
Jun-29-26DowngradeB of A SecuritiesNeutralUnderperform
Mar-17-26DowngradePiper SandlerOverweightNeutral
Jun-12-25DowngradeNeedhamBuyHold
May-01-25ReiteratedNeedhamBuy$97$61
Apr-28-25DowngradeStifelBuyHold
Feb-06-25DowngradeJP MorganOverweightNeutral
Oct-04-24ReiteratedNeedhamBuy$107$97
Apr-25-24ReiteratedNeedhamBuy$107
Latest News· Times ET
Sep-18-26
Sep-16-26
Sep-08-26
Sep-03-26
Aug-28-26
Aug-26-26
Aug-18-26
Aug-17-26
Aug-14-26
Jul-30-26
Company

CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,3721,3741,307
Cost of Goods Sold Incl. D&A621649574
Gross Profit751725733
Selling, General and Administrative Excl. Other545528478
Research and Development615654
Other Operating Expense-201
Operating Income147141200
Interest Expense303137
Unusual Expense
Non-Operating Income (Expense)-35-390
Net Income Before Taxes8271163
Income Taxes272431
Consolidated Net Income5747132
Net Income From Continuing Operations5747132
Net Income5747132
EPS (Recurring)1.851.524.29
EPS (Basic, Before Extraordinaries)1.851.524.29
EPS (Diluted)1.851.514.26
EBITDA179155272
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio24.5526.8916.07
Price To Sales Ratio0.990.921.62
Gross Margin54.7452.7756.08
Operating Margin10.7110.2615.30
Net Margin4.153.4210.10
Shares Outstanding303131
Market Capitalization1,3631,2592,122
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$59.37$51.66$43.96$36.26$28.55 Close Price0.00K40.27K80.55K120.82K161.09KUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kelderman KimDirectorSep 08 '26Option Exercise0.005000500Sep 10
Lalomia BrentExecutive VP RA, QAMar 06 '26Option Exercise0.00750941Mar 10
Kaye MarkDirectorFeb 24 '26Option Exercise0.001520152Feb 26
Glaze RichardChief Information OfficerNov 21 '25Sale41.2125710,5910Nov 24
Glaze RichardChief Information OfficerNov 20 '25Option Exercise0.003750375Nov 21
Garner Todd WExecutive Vice President & CFONov 06 '25Sale43.003,500150,5001,836Nov 07
Foust Hollie KGeneral Counsel & Corp SecNov 04 '25Option Exercise0.004,00004,000Nov 05
Garner Todd WExecutive Vice President & CFOOct 31 '25Option Exercise0.007,50007,500Nov 03
Farkas CharlesDirectorSep 12 '25Sale53.522,000107,04914,859Sep 15
Garner Todd WExecutive Vice President & CFOAug 07 '25Sale52.4559831,3650Aug 08
Bronson David M.DirectorJun 03 '25Option Exercise0.00479017,241Jun 04
Concannon BrianDirectorJun 03 '25Option Exercise0.00479010,116Jun 04
Schwarzentraub Barbara JDirectorJun 03 '25Option Exercise0.0047904,344Jun 04
Aronson Martha GoldbergDirectorJun 03 '25Option Exercise0.00479012,391Jun 04
Council LaVerne HDirectorJun 03 '25Option Exercise0.0047904,048Jun 04
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.